Left ventricular assist devices (LVADs) are increasingly used in patients with end-stage heart failure (HF). There is a significant risk of HF admissions and hemocompatibility-related adverse events that can be minimized by optimizing the LVAD support.

Editors

JACC Heart Failure Editor-in-Chief
Biykem Bozkurt, MD, PhD, FACC 

Deputy Editor
Akshay S. Desai, MD, MPH 

JACC Heart Failure CME/MOC Editor
Kenneth A. Ellenbogen, MD

Author
Bhaskar Arora, MD, FACC 

Important Dates

Date of Release: January 2, 2024
Term of Approval/Date of CME/MOC Expiration: January 1, 2025